India Ceftriaxone Market to be grow by CAGR of 4.31% through forecast period
Growing prevalence of bacterial
infections is expected to drive the India Ceftriaxone Market in the forecast period 2026-2030
According to TechSci Research report, “India
Ceftriaxone Market - By Region, Competition, Forecast
& Opportunities, 2030”, The India Ceftriaxone
Market was valued at USD 205.65 Million in 2024 and is expected to reach USD 262.72
Million by 2030, growing with a CAGR of 4.31% in the forecast period.
The
India Ceftriaxone market is poised for continued expansion, underpinned by the
country’s growing healthcare needs and evolving treatment protocols.
Ceftriaxone, a third-generation cephalosporin antibiotic, plays a crucial role
in the treatment of a wide range of moderate to severe bacterial infections
including pneumonia, urinary tract infections, bloodstream infections,
gonorrhea, meningitis, and post-surgical infections. Its strong efficacy,
broad-spectrum activity, and once-daily intravenous or intramuscular dosing
make it a preferred choice among healthcare providers, particularly in hospital
and critical care settings. As public health awareness increases and more
patients seek formal medical care, the demand for injectable antibiotics such
as Ceftriaxone continues to rise.
Government initiatives have significantly supported the
market. Schemes like Ayushman Bharat, which aims to provide free healthcare to
over 500 million Indians, and the expansion of Health and Wellness Centres
across the country have improved access to healthcare services, especially in
rural and semi-urban regions. This has led to an increase in hospital
admissions and diagnostic interventions, both of which drive the usage of
antibiotics. Public hospitals and state governments procure Ceftriaxone in large
volumes through centralized tender systems, ensuring its presence on the front
lines of infection management.
Browse over XX market data Figures
spread through XX Pages and an in-depth TOC on "India Ceftriaxone Market ”
The India Ceftriaxone Market is segmented into dose, source,
form, distribution channel, application, end user, regional distribution, and
company.
Based on source, Contract Manufacturing Organizations
(CMOs) dominated the Ceftriaxone market segment in India due to their
cost-efficiency, scale, and regulatory expertise. Ceftriaxone is listed under
the National List of Essential Medicines (NLEM), subjecting it to price caps
set by the National Pharmaceutical Pricing Authority (NPPA). These price
controls reduce profit margins, making in-house manufacturing less viable for
many pharmaceutical companies. CMOs offer a practical solution by producing
high volumes at lower costs, leveraging economies of scale and established
manufacturing infrastructure. Many Indian CMOs are WHO-GMP certified and
operate in pharmaceutical hubs like Gujarat, Himachal Pradesh, and Telangana,
making them well-positioned to handle bulk production for both domestic supply
and exports. Their ability to meet strict regulatory requirements while keeping
production costs low makes them ideal partners for brand owners who prefer to
focus on marketing, distribution, and compliance. This outsourcing model allows companies to remain
competitive in a highly price-sensitive market while ensuring consistent
quality and timely delivery. As demand for Ceftriaxone remains high, reliance
on CMOs continues to grow across the Indian pharmaceutical landscape.
Based on end user, In the India Ceftriaxone market,
the adult segment was the dominant consumer compared to the paediatric segment.
This dominance is largely due to the high burden of severe bacterial infections
among adults, including pneumonia, urinary tract infections, sepsis, and
post-surgical infections, which often require hospitalization and parenteral
antibiotic treatment. Ceftriaxone is widely used as a first-line injectable
antibiotic in adult patients, especially in emergency and critical care
settings, where rapid and broad-spectrum bacterial coverage is essential. Public and private hospitals in India predominantly
treat adult patients with standardized 1g or higher dosage strengths, which
aligns with adult dosing requirements. Government procurement for public health
schemes also focuses heavily on adult treatment regimens, as adults form the
largest share of the working population and hospital admissions. In contrast, the paediatric segment, though
significant, uses lower dosages and has more limited demand due to smaller
patient volumes and strict dosing protocols. As a result, adult usage drives
the bulk of Ceftriaxone sales in India, supported by healthcare infrastructure,
clinical protocols, and procurement policies favoring adult indications.
Based on region, Southern India is the fastest-growing
region in the India Ceftriaxone market. This growth is fueled by a strong
healthcare infrastructure, increasing hospital admissions, rising surgical
volumes, and a proactive public health ecosystem. States like Tamil Nadu,
Karnataka, Telangana, and Andhra Pradesh have well-established networks of
government and private hospitals that frequently use Ceftriaxone for inpatient
and critical care. The region also benefits from better healthcare
awareness, early diagnosis, and higher per capita health expenditure compared
to many other parts of the country. Southern states have been at the forefront
of implementing national health schemes like Ayushman Bharat and expanding
Health and Wellness Centres, leading to more referrals for secondary and
tertiary care. In addition, Southern India is home to several WHO-GMP certified
pharmaceutical manufacturing hubs, particularly in Hyderabad (Telangana) and
Bengaluru (Karnataka). This concentration of manufacturing expertise supports
the rapid supply of antibiotics like Ceftriaxone to both local and national
markets. These combined factors make Southern India the fastest-growing
regional market for Ceftriaxone in the country.
Major companies operating in India
Ceftriaxone Market are:
·
Radicura
Pharmaceuticals Pvt. Ltd
·
Wockhardt Limited
(Taurus)
·
Nectar Lifesciences
Ltd.
·
Qilu Pharmaceutical
India Pvt. Ltd.
·
Mankind Pharma Ltd.
·
Fresenius Kabi India
Pvt. Ltd.
·
Virchow Healthcare
Private Limited
·
Orchid Pharma Ltd.
·
Ikon Remedies Pvt.
Ltd.
·
IPCA Laboratories
Ltd
Download Free Sample Report
Customers can also request for 10%
free customization on this report.
“The India Ceftriaxone market is growing steadily,
driven by rising infection rates, hospital admissions, and government-backed
healthcare initiatives. Ceftriaxone, a widely used injectable antibiotic, is
essential in treating serious bacterial infections across public and private
hospitals. Demand is particularly strong in tertiary care and emergency
settings due to its broad-spectrum efficacy and once-daily dosing. Increasing
adoption in rural health programs and expansion of surgical procedures are further
boosting consumption. Contract Manufacturing Organizations dominate production
due to pricing pressures and large-scale procurement needs. With expanding
infrastructure and awareness, Ceftriaxone remains a critical component of
India’s essential medicines landscape” said Mr. Karan Chechi, Research Director
of TechSci Research, a research-based management consulting firm.
“India Ceftriaxone Market By Dose (100 mg, 200 mg, 250 mg, 500 mg and Others), By Source (In-house v/s Contract Manufacturing Organizations), By Form (Intramuscular Injection, Intravenous Injection, Infusion, Others), By Distribution Channel (Online v/s Offline), By Application (Endocarditis, Meningitis, Pneumonia, Bone and Joint Infections, Intra-Abdominal Infections, Skin Infections, Urinary Tract Infections, Gonorrhoea, Others), By End User (Adult v/s Paediatric), By Company, By Region, Forecast & OppoBy Region, Competition, Forecast & Opportunitiesrtunities, 2020-2030F”, has evaluated the future growth
potential of India Ceftriaxone Market and provides statistics & information on
market size, structure and future market growth. The report intends to provide
cutting-edge market intelligence and help decision makers take sound investment
decisions. Besides, the report also identifies and analyzes the emerging trends
along with essential drivers, challenges, and opportunities in India
Ceftriaxone Market.
Contact
TechSci
Research LLC
420
Lexington Avenue, Suite 300,
New
York, United States- 10170
Tel: +1-332-258-6602
Email: [email protected]
Website: www.techsciresearch.com